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Introduction
CAPS is a rare autoinflammatory disease associated with
mutations in the NLRP3 gene that result in overactiva-
tion of the inflammasome, increased secretion of
IL-1beta and IL-18, and systemic inflammation. Mutations
in the NLRP3 gene on chromosome 1q44 causes cryopyri-
nopathies. These are autosomal dominant disorders with
varying penetrance, which may also present de novo.
MWS is an intermediate phenotype characterized
by chronic or intermittent episodes of fever, headache,
urticarial rash, arthralgias or arthritis, CNS involvement,
ocular disorders and progressive deafness. Treatment is
based on IL-1 antagonism, which usually results in prompt
clinical response and may prevent amyloidosis.
Methods
Here we present a family whose 11 members have similar
symptoms. Clinical data is collected during the course of
ongoing patient care.
Results
We evaluated the clinical features of 11 patients who were
referred to our center. The median age of the patients was
25 years (range: 9-65 years). The ratio of females /males
was 1.2 (6/5). All patients had arthritis with exacerbation
on exposure to cold and ocular involvement, mostly in the
form of conjunctivitis and far less commonly uveitis, iri-
deal synechiae, band keratopathy, cataract, and impaired
vision. The median age of onset of arthritis was 7 years
(2-30 y), the median age of onset of ocular involvement
was 8 years (2-45 y). Hearing loss in 73.6% of patients was
detected. The median age of onset of hearing loss was
15 years (12-63 y). All patient except one had urticarial
rash. The median age of onset of urticarial rash was
8 years (7-30 y). Genetic testing for mutations of NLRP3
gene has not done yet.
Two patients were treated with canakunimab (Ilaris,
Novartis, Switzerland) which is a human anti-IL-1 beta
monoclonal antibody given by subcutaneous injections
every 8 weeks (2mg/kg). Following canakunimab treat-
ment, attacks of arthritis and urticaria are getting fully
under control, advances in keratopathy and hearing loss
could be partially controlled.
Discussion
MWS is characterized by recurrent fever and urticarial
rash, progressive sensorineural deafness and the develop-
ment of secondary amyloidosis. Treatment is based on
IL-1 antagonism, which usually results in prompt clinical
response and may prevent amyloidosis.
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